Parkinson DiseaseREACH-PDNCT05908266
Flexible Reaching Control in Parkinson Disease
An observational study of Parkinson Disease, run by Université Catholique de Louvain at 1 site in Belgium.
Trial summary
Current research and theories have highlighted that the parameters linked to movement planning, e.g. the decision to select a movement goal, and adaptation, e.g. the ability to update control dependent on a novel dynamical context, are update quickly and within an ongoing movement in the general population. Read more about this study
- Who is it for?
- Ages 18 to 99 yearsHealthy volunteers can take part
- Conditions the study is for
- Parkinson Disease
- What is being tested?
- Reaching movements and Disease Assessment
- How many people
- 100 participants
- Where
- 1 siteBelgium
- Study dates
- 1 May 2023to 31 Oct 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study will be based on two populations: on population of volunteers with Parkinson disease, and one population of age and sex matched healthy individuals.
Who may be able to join
- Ability to perform the task (assessed during the experiment)
Who cannot join
- Inability to perform the task (motor) or to understand the task requirements (cognitive)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Frédéric Crevecoeur, PhD contact
Belgium1 site, 1 recruiting
- Recruiting
Université catholique de Louvain
Louvain-la-Neuve, 1348
André Mouraux, PhD, +32 2 764 54 47, andre.mouraux@uclouvain.be
About this study
Official title: Behavioural Study of Reaching Control in Healthy Volunteers and Volunteers With Parkinson Disease in Dynamical Context
Current research and theories have highlighted that the parameters linked to movement planning, e.g. the decision to select a movement goal, and adaptation, e.g. the ability to update control dependent on a novel dynamical context, are update quickly and within an ongoing movement in the general population. In parallel, it has been suggested that the evaluation of movement costs is a function of the basal ganglia, and it is impaired in Parkinson disease (PD). Here the investigators want to test whether these mechanisms also alter the ability of patients to update control during an ongoing action. A positive result would confirm that movement-related costs and dynamical representations depend on the integrity of the basal ganglia, in contrast a negative result would indicate that the deficit in PD is more specifically related to movement initiation, which would invite one to reconsider the cause of bradykinesia in this population.
- Conditions
- Parkinson Disease
- Being tested
- Reaching movements, Disease Assessment
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Reaching movementsOther
Participants will be instructed to perform reaching movements by moving the handle of a robotic arm mounted with a virtual reality display.
Disease AssessmentOther
Disease stage assessed by trained professionals
| Study group | Role | What they receive |
|---|---|---|
| PD | Patients with Parkinson disease Receives: Other: Reaching movements; Other: Disease Assessment | |
| Control | Healthy volunteers Receives: Other: Reaching movements |
What is being measured
The primary outcome is the main question the study is designed to answer.
Kinematics
Position of the handle as a function of time. Units are millimetres
Measured: Measured during the entire experiment (an average of 4.5 years)
Surface Electromyogram
Surface recordings of muscles activities from the main muscles involved in movement production. Units are volts
Measured: Measured during the entire experiment (an average of 4.5 years)
Applied forces
Forces applied by participants on the robotic handle. Units are Newtons
Measured: Measured during the entire experiment (an average of 4.5 years)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jun 2023
- Study start1 May 2023
- Primary completion31 Oct 2027 (estimated)
- Study completion31 Oct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Université Catholique de Louvain
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Frédéric Crevecoeur, PhD, Study director, Université Catholique de Louvain
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05908266
- Sponsor's protocol ID
- REACH-PD
- Acronym
- REACH-PD
- Status last verified
- Jun 2023
- First submitted
- 25 May 2023
- Last updated
- 18 Jun 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Behavioural Study of Reaching Control in Healthy Volunteers and Volunteers With Parkinson Disease in Dynamical Context
- ClinicalTrials.gov ID
- NCT05908266
- Acronym / sponsor ID
- REACH-PD / REACH-PD
- Conditions
- Parkinson Disease
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Université Catholique de LouvainUniversity, hospital or other
- Study start
- 1 May 2023 (actual)
- Primary completion
- 31 Oct 2027 (estimated)
- Study completion
- 31 Oct 2027 (estimated)
- First posted
- 18 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Current research and theories have highlighted that the parameters linked to movement planning, e.g. the decision to select a movement goal, and adaptation, e.g. the ability to update control dependent on a novel dynamical context, are update quickly and within an ongoing movement in the general population. In parallel, it has been suggested that the evaluation of movement costs is a function of the basal ganglia, and it is impaired in Parkinson disease (PD). Here the investigators want to test whether these mechanisms also alter the ability of patients to update control during an ongoing action. A positive result would confirm that movement-related costs and dynamical representations depend on the integrity of the basal ganglia, in contrast a negative result would indicate that the deficit in PD is more specifically related to movement initiation, which would invite one to reconsider the cause of bradykinesia in this population.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| PD | – | Other: Reaching movements, Other: Disease AssessmentPatients with Parkinson disease |
| Control | – | Other: Reaching movementsHealthy volunteers |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study will be based on two populations: on population of volunteers with Parkinson disease, and one population of age and sex matched healthy individuals.
Key inclusion criteria (1 listed)
- Ability to perform the task (assessed during the experiment)
Key exclusion criteria (1 listed)
- Inability to perform the task (motor) or to understand the task requirements (cognitive)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Reaching movementsParticipants will be instructed to perform reaching movements by moving the handle of a robotic arm mounted with a virtual reality display. | Other | Control, PD |
| Disease AssessmentDisease stage assessed by trained professionals | Other | PD |
Primary outcome
Kinematics
Time frame: Measured during the entire experiment (an average of 4.5 years)
Position of the handle as a function of time. Units are millimetres
Surface Electromyogram
Time frame: Measured during the entire experiment (an average of 4.5 years)
Surface recordings of muscles activities from the main muscles involved in movement production. Units are volts
Applied forces
Time frame: Measured during the entire experiment (an average of 4.5 years)
Forces applied by participants on the robotic handle. Units are Newtons
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2023.
- Individual participant dataSharing planned: No
Related trials for Parkinson Disease
Recruiting
OCT-Angiography and Adaptive Optics in Patients With Memory Impairment
Amnesia, Alzheimer Disease
Not yet recruitingPhase 2
Estimates of the Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease
Parkinson Disease
RecruitingPhase 3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Carcinoma, Non-Small-Cell Lung
RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Parkinson Disease, Parkinson
Active, not recruitingPhase 2
A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease
Parkinson&Amp;#39;s Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Frédéric Crevecoeur, PhD contact
Frédéric Crevecoeur, PhD study director
Université Catholique de Louvain
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Parkinson Disease, run by Université Catholique de Louvain at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact André Mouraux, PhD (+32 2 764 54 47, andre.mouraux@uclouvain.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Kinematics (time frame: Measured during the entire experiment (an average of 4.5 years)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2023; AzTrials last refreshed its copy on 31 Oct 2026.